Product Description
Diltiazem is used to treat high blood pressure and to control angina (chest pain). Diltiazem is in a class of medications called calcium-channel blockers. It works by relaxing the blood vessels so the heart does not have to pump as hard. It also increases the supply of blood and oxygen to the heart. (Sourced from: https://medlineplus.gov/druginfo/meds/a684027.html)
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intravenous, Topical
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: BeiGene
Company Location:
Company CEO: John V. Oyler
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Microvascular Angina
Phase 1: Healthy Volunteers|Pain Unspecified|Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06692647 |
MK-4318-003 | P1 |
Completed |
Pain Unspecified|Healthy Volunteers |
2024-04-11 |
2024-11-19 |
Primary Endpoints|Treatments |
|
NCT06554639 |
MK-5684-011 | P1 |
Completed |
Prostate Cancer |
2024-08-05 |
21% |
2024-10-16 |
Primary Completion Date|Primary Endpoints|Treatments |
2018-003518-41 |
EDIT-CMD | P2 |
Active, not recruiting |
Microvascular Angina |
2024-07-24 |
2022-03-13 |
Treatments |
|
NCT06703463 |
MK-1167-006 | P1 |
Completed |
Healthy Volunteers |
2024-02-02 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT06818968 |
MK-6916-005 | P1 |
Completed |
Healthy Volunteers |
2025-08-08 |
88% |
2025-08-27 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
NCT07232589 |
MK-1026-022 | P1 |
Recruiting |
Healthy Volunteers |
2026-02-01 |
88% |
2025-12-13 |
Primary Endpoints|Treatments|Trial Status |
NCT06662396 |
MK-6552-007 | P1 |
Completed |
Healthy Volunteers |
2024-09-27 |
2024-10-30 |
Primary Endpoints|Treatments |